Managing the teratogenic risk of thalidomide and lenalidomide: an industry perspective

Author： Bwire Robert   Freeman John   Houn Florence  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.10, Iss.1, 2011-01, pp. : 3-8

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

High VTE rates with thalidomide, lenalidomide

By  

Reactions Weekly, Vol. 1, Iss. 1133, 2007-01 ,pp. : 1-1

Adis International

Access to resources Recommend Favorite

Lenalidomide and thalidomide in the treatment of chronic pain

By Asher Christopher   Furnish Timothy  

Expert Opinion on Drug Safety, Vol. 12, Iss. 3, 2013-05 ,pp. : 367-374

Informa Healthcare

Access to resources Recommend Favorite

No significant teratogenic risk with sulfasalazine

By  

Inpharma, Vol. 1, Iss. 1288, 2001-01 ,pp. : 21-21

Adis International

Access to resources Recommend Favorite

An Industry Perspective on the Erice Declaration and Risk Minimisation Plans

By Ingate Simon   Tranter Deborah   Banerjee Anjan   Hobbs Andrew  

Drug Safety, Vol. 29, Iss. 8, 2006-01 ,pp. : 733-734

Adis International

Access to resources Recommend Favorite

The Art and Science of Risk Management: A US Research-Based Industry Perspective

By Janice K. Bush  

Drug Safety, Vol. 28, Iss. 1, 2005-01 ,pp. : 1-18

Adis International

Access to resources Recommend Favorite